Research Roundup

Debbie Rigby 20/05/2025

Debbie Rigby rounds up the latest in research news Calcitonin gene-related peptide–targeted therapies for migraine Calcitonin gene-related peptide (CGRP)–targeted therapies are the first medications developed specifically for migraine prevention. CGRP monoclonal antibodies are available as self-administered subcutaneous injections or as an intravenous infusion, and are administered monthly or quarterly. Small-molecule CGRP receptor antagonists (known as

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

This web site is intended for Australian pharmacy professionals and is not a substitute for independent professional advice. Information and interactions contained in this website are for information purposes only and are not intended to be used to diagnose, treat, cure or prevent any disease. Further the accuracy, currency and completeness of the information available on this web site cannot be guaranteed. APPco Pty Ltd, its affiliates and their respective servants and agents do not accept any liability for any injury, loss or damage incurred by use of or reliance on the information made available via or through ajp.com.au whether arising from negligence or otherwise.

Research Roundup

Previous True accessibility means safe environments: Sim

Next Vic govt to fund pharmacist consults

MENU

ajp.com.au

Previous True accessibility means safe environments: Sim

Next Vic govt to fund pharmacist consults

MENU

ajp.com.au

Tags

Hi there! 👋 Looks like you’re not logged in.